Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

InMed Conferences and Events

Upcoming Events

Benzinga Cannabis Capital Conference

Date: Sept. 27-28, 2023

Time: 11:40am CT

InMed’s subsidiary, BayMedica, will be participating at the upcoming Benzinga Cannabis Capital Conference September 27-28th in Chicago, IL.

Jerry Griffin, VP of Sales and Marketing at BayMedica, will be joining a panel discussion “Transforming the CPG Landscape: Why Rare Cannabinoids Ingredients are the Next Big Thing.”

Panel Discussion takes place Thursday, September 28 at 11:40am CT

Learn more about the speakers here.

 

Add to Calendar

Past Events

H.C. Wainwright 25th Annual Global Investment Conference

Date: Sept. 11-13, 2023

Time: 7:00am

InMed will be participating in the H.C. Wainwright 25th Annual Global Investment Conference in New York City from September 11-13, 2023. CEO Eric A. Adams will present at the conference.

On-demand presentation available here. Presentation will be accessible for 90 days.

InMed’s management team will be available for onsite and virtual one-on-one meetings with registered investors during the conference. To request 1-on-1 meetings with the Company, please contact your H.C Wainwright institutional representative.

Add to Calendar

Investor Summit

Date: June 1, 2023

Time: 11:30am ET

Eric A. Adams, CEO of InMed, will present a corporate overview followed by a Q&A session. Management will be available for virtual one-on-one meetings for qualified investors. The conference is complimentary to qualified investors. Please register through Investor Summit.

Register here to watch the recorded presentation on demand.

Add to Calendar

Tribe Public Webinar

Date: May 31, 2023

Time: 12:00pm ET

Eric A. Adams, CEO of InMed, and Jerry Griffin, VP, Sales and Marketing of BayMedica, will co-host a presentation event titled, “Addressing The Increasing Demand For Rare Cannabinoids”.

Management will be available for a 5-10 minute Q&A session at the end of the presentation. Please send your questions for management to Tribe’s email: [email protected].

Watch the webinar recording here.

Add to Calendar

Fireside Chat with Water Tower Research

Date: May 23, 2023

Time: 1:00pm ET

InMed’s CEO, Eric A. Adams, will join Robert Sassoon of Water Tower Research for a Fireside Chat.

Join the meeting where they’ll discuss:

  • InMed’s rare cannabinoid pharmaceutical programs in Epidermolysis Bullosa, Glaucoma and Neurodegenerative diseases
  • Bioidentical rare cannabinoid sales by BayMedica, InMed’s subsidiary
  • Upcoming catalysts

Register here to watch webcast recording.

Add to Calendar

VirtualInvestorConferences.com – Life Sciences Investor Forum

Date: March 9, 2023

Time: 11:00am ET

VirtualInvestorConferences.com – Life Sciences Investor Forum

InMed’s CEO, Mr Eric A. Adams, will perform a presentation followed by a questions and answers session. Management will be available for virtual one-on-one meetings with institutional and individual investors from March 9 – March 14.

Registration: https://bit.ly/3IoXpvP

Learn more about the event at www.virtualinvestorconferences.com

Add to Calendar

Emerging Growth Conference

Date: March 8, 2023

Time: 12:30pm ET

Emerging Growth Conference

InMed’s CEO, Mr. Eric A. Adams, will perform a presentation followed by a questions and answers session. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.

Watch the presentation here on demand

 

Add to Calendar

Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids”

Date: November 17, 2022

Time: 8am PT / 11am ET

Registration Now Open For Tribe Public’s Webinar Event “Exploring the Neuroprotective Qualities of Rare Cannabinoids” Featuring InMed’s Management Team On November 17, 2022

Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development.

Date: November 17, 2022
Time: 8:00am PST / 11:00am EST

To register to join the complimentary, ZOOM webinar-based event, please visit Tribe Public LLC at INMNOV17.TribePublic.com. Once registered, participants may begin forwarding their questions for InMed’s  management to Tribe Public at [email protected] or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.

Add to Calendar

Force For Knowledge Cannabis Symposium – Jump Starting Cannabis Valuations 101

Date: June 29, 2022

Time: 12:00pm ET

Dr. Shane Johnson, GM and SVP of BayMedica, InMed’s subsidiary, will be joining the panel presentation “The Intersection Between Medical and Health & Wellness” with Radicle Science’s Dr. Jeff Chen.

A discussion of the opportunities in pharmaceutical industry in addition to current health & wellness uses.

  • Shane Johnson, SVP, BayMedica a Division of InMed Pharmaceuticals
  • Jeff Chen, MD & MBA, CEO & Co-founder, Radicle Science

RSVP at : https://forcefamilyoffice.com/events/technology/2022-06-22-force-knowledge-cannabis/

Add to Calendar

H.C. Wainwright Global Investment Conference

Date: May 23-26, 2022

Presentation: The webcast recording will available on this page. Please check back for the link to access the webcast.

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your H.C. Wainwright institutional representative.

More information about the H.C. Wainwright Global Investment Conference can be found here.

Add to Calendar

Canaccord Genuity’s 6th Annual Global Cannabis Conference

Date: May 11, 2022

Presentation: The webcast recording will be posted on this page. Check back for the link.

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Canaccord institutional representative. More information on the Canaccord Cannabis Conference can be found here.

Add to Calendar
Load More


INM-755

A cannabinol (CBN) topical cream which has completed a Phase 2 clinical trial for epidermolysis bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • INM-900 Series for Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*